WHO invites bio prequalification

  
Generate a summary of this article
Listen to this article
Beta

An invitation to participate in a pilot procedure for the prequalification of both branded and biosimilar rituximab and trastuzumab has been published by the World Health Organization (WHO). First announced last year (Generics bulletin, 15 September 2017, page 5) – after the WHO announced that it would start prequalifying the two oncology treatments (Generics bulletin, 12 May 2017, page 13) – the scheme, titled ‘pilot procedure for prequalification of biotherapeutic products and similar biotherapeutic products’, has been billed by the WHO as “a step forward to support national and global efforts to increase access to and the affordability of biotherapeutic products and their corresponding similar biotherapeutic products”.

An invitation to participate in a pilot procedure for the prequalification of both branded and biosimilar rituximab and trastuzumab has been published by the World Health Organization (WHO). First announced last year (Generics bulletin, 15 September 2017, page 5) – after the WHO announced that it would start prequalifying the two oncology treatments (Generics bulletin, 12 May 2017, page 13) – the scheme, titled ‘pilot procedure for prequalification of biotherapeutic products and similar biotherapeutic products’, has been billed by the WHO as “a step forward to support national and global efforts to increase access to and the affordability of biotherapeutic products and their corresponding similar biotherapeutic products”.

If products meet WHO standards, they will be included on the WHO list of prequalified products acceptable in principle for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.